A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
Abstract Increasing evidence has shown that Parkinson’s disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential therapeutic target for synucleinopathies. A brain-penetrant SCD inhibitor, YTX-7739, was developed and has entered Phase 1 clinical trials. Here, we report the efficacy of YTX-7739 in reversing pathological αSyn phenotypes in various in vitro and in vivo PD models. In cell-based assays, YTX-7739 decreased αSyn-mediated neuronal death, reversed the abnormal membrane interaction of amplified E46K (“3K”) αSyn, and prevented pathological phenotypes in A53T and αSyn triplication patient-derived neurospheres, including dysregulated fatty acid profiles and pS129 αSyn accumulation. In 3K PD-like mice, YTX-7739 crossed the blood–brain barrier, decreased unsaturated fatty acids, and prevented progressive motor deficits. Both YTX-7739 treatment and decreasing SCD activity through deletion of one copy of the SCD1 gene (SKO) restored the physiological αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival in 3K αSyn mice. YTX-7739 efficiently reduced pS129 + and PK-resistant αSyn in both human wild-type αSyn and 3K mutant mice similar to the level of 3K-SKO. Together, these data provide further validation of SCD as a PD therapeutic target and YTX-7739 as a clinical candidate for treating human α-synucleinopathies..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
NeuroRX - 19(2022), 3 vom: Apr., Seite 1018-1036 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Nuber, Silke [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
© The Author(s) 2022. corrected publication 2022 |
---|
doi: |
10.1007/s13311-022-01199-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR047630221 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR047630221 | ||
003 | DE-627 | ||
005 | 20230519183233.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220719s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13311-022-01199-7 |2 doi | |
035 | |a (DE-627)SPR047630221 | ||
035 | |a (SPR)s13311-022-01199-7-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Nuber, Silke |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2022. corrected publication 2022 | ||
520 | |a Abstract Increasing evidence has shown that Parkinson’s disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential therapeutic target for synucleinopathies. A brain-penetrant SCD inhibitor, YTX-7739, was developed and has entered Phase 1 clinical trials. Here, we report the efficacy of YTX-7739 in reversing pathological αSyn phenotypes in various in vitro and in vivo PD models. In cell-based assays, YTX-7739 decreased αSyn-mediated neuronal death, reversed the abnormal membrane interaction of amplified E46K (“3K”) αSyn, and prevented pathological phenotypes in A53T and αSyn triplication patient-derived neurospheres, including dysregulated fatty acid profiles and pS129 αSyn accumulation. In 3K PD-like mice, YTX-7739 crossed the blood–brain barrier, decreased unsaturated fatty acids, and prevented progressive motor deficits. Both YTX-7739 treatment and decreasing SCD activity through deletion of one copy of the SCD1 gene (SKO) restored the physiological αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival in 3K αSyn mice. YTX-7739 efficiently reduced pS129 + and PK-resistant αSyn in both human wild-type αSyn and 3K mutant mice similar to the level of 3K-SKO. Together, these data provide further validation of SCD as a PD therapeutic target and YTX-7739 as a clinical candidate for treating human α-synucleinopathies. | ||
700 | 1 | |a Chung, Chee Yeun |0 (orcid)0000-0002-5515-650X |4 aut | |
700 | 1 | |a Tardiff, Daniel F. |4 aut | |
700 | 1 | |a Bechade, Pascal A. |4 aut | |
700 | 1 | |a McCaffery, Thomas D. |4 aut | |
700 | 1 | |a Shimanaka, Kazuma |4 aut | |
700 | 1 | |a Choi, Jeonghoon |4 aut | |
700 | 1 | |a Chang, Belle |4 aut | |
700 | 1 | |a Raja, Waseem |4 aut | |
700 | 1 | |a Neves, Esther |4 aut | |
700 | 1 | |a Burke, Christopher |4 aut | |
700 | 1 | |a Jiang, Xin |4 aut | |
700 | 1 | |a Xu, Ping |4 aut | |
700 | 1 | |a Khurana, Vikram |4 aut | |
700 | 1 | |a Dettmer, Ulf |4 aut | |
700 | 1 | |a Fanning, Saranna |4 aut | |
700 | 1 | |a Rhodes, Kenneth J. |4 aut | |
700 | 1 | |a Selkoe, Dennis J. |4 aut | |
700 | 1 | |a Scannevin, Robert H. |4 aut | |
773 | 0 | 8 | |i Enthalten in |t NeuroRX |d Springer-Verlag, 2006 |g 19(2022), 3 vom: Apr., Seite 1018-1036 |w (DE-627)SPR031264964 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2022 |g number:3 |g month:04 |g pages:1018-1036 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13311-022-01199-7 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 19 |j 2022 |e 3 |c 04 |h 1018-1036 |